Application of T-LAK cell-originated protein kinase (TOPK) serving as cisplatin resistance therapy target for cervical cancer

Abstract

The invention belongs to the field of anti-cervical cancer drugs, and particularly relates to application of T-LAK cell-originated protein kinase (TOPK) serving as a cisplatin resistance therapy target for cervical cancer. In the prior art, a relationship between the TOPK and cervical cancer proliferation and cisplatin resistance is not yet studied. In order to clarify the mechanism of cisplatin resistance of cervical cancer patients, and provide a better therapeutic drug for the cervical cancer patients, the invention conducts a series of researches on the influences of TOPK on cervical cancer proliferation and cisplatin resistance. Results show that the TOPK is highly expressed in tissue of the cervical cancer patients, the TOPK promotes proliferation of cervical cancer cells, and overexpression of the TOPK promotes cisplatin resistance of the cervical cancer cells. A further study shows that a TOPK specific inhibitor OTS514 significantly inhibits proliferation of the cervical cancercells in vivo and in vitro, and the TOPK inhibitor OTS514 and cisplatin are combined and applied to therapy of the cervical cancer, and the therapy effect is superior to a pure cisplatin cisplatin therapy effect.

Description

technical field [0001] The invention belongs to the technical field of cervical cancer treatment targets, and specifically relates to TOPK as a cisplatin-resistant treatment target for cervical cancer, and the application of TOPK inhibitors and cisplatin in combination for cervical cancer treatment. Background technique [0002] The information disclosed in this background section is only intended to increase the understanding of the general background of the present invention, and is not necessarily taken as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to those skilled in the art. [0003] The incidence of cervical cancer ranks fourth among female patients in the world. According to the annual statistical report of the American Cancer Society, there will be 61,880 new cases of cervical cancer in the United States in 2019, and 12,160 deaths. In China, there are 131,500 new cases of cervical cancer each year, and th...

AI Technical Summary

Problems solved by technology

However, the relationship between TOPK and malignant progression

Images